<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144206</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00065596</org_study_id>
    <nct_id>NCT03144206</nct_id>
  </id_info>
  <brief_title>Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection</brief_title>
  <official_title>Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized investigation with appropriate power would determine whether or not&#xD;
      postoperative hyperbaric oxygen therapy improves wound healing in patients with soft tissue&#xD;
      sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Complications</measure>
    <time_frame>24 weeks postoperatively</time_frame>
    <description>number of patients with wound complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical site infections or periprosthetic infections</measure>
    <time_frame>24 weeks postoperatively</time_frame>
    <description>number of patients with Surgical site infections or periprosthetic infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local wound management</measure>
    <time_frame>24 weeks postoperatively</time_frame>
    <description>Number of patients requiring local wound management (such as wound packing, negative pressure therapy or other advanced dressings/wound care techniques)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation due to wound complications</measure>
    <time_frame>24 weeks postoperatively</time_frame>
    <description>Number of patients requiring reoperation due to wound complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Sarcoma</condition>
  <condition>Hyperbaric Oxygen Therapy</condition>
  <arm_group>
    <arm_group_label>Hyperbaric Oxygen Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen</intervention_name>
    <description>Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period</description>
    <arm_group_label>Hyperbaric Oxygen Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females within the ages of 18-85&#xD;
&#xD;
          2. Diagnosis of soft tissue sarcoma that has been histologically confirmed by an approved&#xD;
             reference pathologist&#xD;
&#xD;
          3. Sarcoma of lower extremity location&#xD;
&#xD;
          4. Treatment plan that includes neo-adjuvant radiation therapy followed by surgical&#xD;
             resection&#xD;
&#xD;
          5. Expected primary wound closure performed at the time at surgery&#xD;
&#xD;
          6. Any disease stage&#xD;
&#xD;
          7. Any tumor grade&#xD;
&#xD;
          8. Any histologic subtype&#xD;
&#xD;
          9. First or recurrent presentations&#xD;
&#xD;
         10. No vascular invasion or resection/repair/reconstruction that results in decreased&#xD;
             perfusion of the extremity&#xD;
&#xD;
         11. No history of radiation therapy to the tumor and/or surgical area prior to the current&#xD;
             treatment being studied&#xD;
&#xD;
         12. Must be able to comply with follow up visits&#xD;
&#xD;
         13. Must be able to provide own consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients under the age of 18, or over the age of 85.&#xD;
&#xD;
          2. Treatment plan that doesn't include neo-adjuvant radiation and surgical excision&#xD;
&#xD;
          3. Sarcoma location other than lower extremity&#xD;
&#xD;
          4. History of radiation therapy to the tumor and/or surgical area prior to the current&#xD;
             treatment being studied&#xD;
&#xD;
          5. High dose steroid therapy (defined as &gt;5mg prednisone, or equivalent, daily)&#xD;
&#xD;
          6. Active treatment with chemotherapy&#xD;
&#xD;
          7. Inability of the patient to provide informed consent (i.e. dementia, cognitive&#xD;
             impairment, non-English speakers)&#xD;
&#xD;
          8. Plan for post operative radiation therapy&#xD;
&#xD;
          9. Vascular invasion or resection/repair/reconstruction that results in decreased&#xD;
             perfusion of the extremity&#xD;
&#xD;
         10. Vascular disease resulting in clinically apparent compromise in blood flow to the&#xD;
             treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous&#xD;
             insufficiency with clinical evidence of vascular congestion)&#xD;
&#xD;
         11. Actively uncontrolled diabetes mellitus (documentation of history of DM with A1c&gt;8)&#xD;
&#xD;
         12. Active deep vein thrombosis in the treatment extremity&#xD;
&#xD;
         13. Inability to comply with follow up visits&#xD;
&#xD;
         14. Pregnant females (women of childbearing potential must have a negative serum pregnancy&#xD;
             test prior to enrollment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Will Eward</last_name>
    <phone>9196135550</phone>
    <email>william.eward@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>DUke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Eward</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

